211 related articles for article (PubMed ID: 35461369)
1. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
3. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
4. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
[TBL] [Abstract][Full Text] [Related]
6. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
[TBL] [Abstract][Full Text] [Related]
7. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice.
Inia JA; Stokman G; Morrison MC; Worms N; Verschuren L; Caspers MPM; Menke AL; Petitjean L; Chen L; Petitjean M; Jukema JW; Princen HMG; van den Hoek AM
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239841
[TBL] [Abstract][Full Text] [Related]
10. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
11. Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Flensted-Jensen M; Oró D; Rørbeck EA; Zhang C; Madsen MR; Madsen AN; Norlin J; Feigh M; Larsen S; Hansen HH
BMC Gastroenterol; 2024 Feb; 24(1):59. PubMed ID: 38308212
[TBL] [Abstract][Full Text] [Related]
12. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
[TBL] [Abstract][Full Text] [Related]
14. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
[TBL] [Abstract][Full Text] [Related]
15. A long-acting LEAP2 analog reduces hepatic steatosis and inflammation and causes marked weight loss in mice.
Shankar K; Metzger NP; Lawrence C; Gupta D; Osborne-Lawrence S; Varshney S; Singh O; Richard CP; Zaykov AN; Rolfts R; DuBois BN; Perez-Tilve D; Mani BK; Hammer STG; Zigman JM
Mol Metab; 2024 Jun; 84():101950. PubMed ID: 38697291
[TBL] [Abstract][Full Text] [Related]
16. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
[TBL] [Abstract][Full Text] [Related]
17. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome.
Kim ER; Park JS; Kim JH; Oh JY; Oh IJ; Choi DH; Lee YS; Park IS; Kim S; Lee DH; Cheon JH; Bae JW; Lee M; Cho JW; An IB; Nam EJ; Yang SI; Lee MS; Bae SH; Lee YH
Hepatology; 2022 Jun; 75(6):1523-1538. PubMed ID: 34773257
[TBL] [Abstract][Full Text] [Related]
18. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
[TBL] [Abstract][Full Text] [Related]
19. Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis.
Kannt A; Papada E; Kammermeier C; D'Auria G; Jiménez-Hernández N; Stephan M; Schwahn U; Madsen AN; Østergaard MV; Dedoussis G; Francino MP;
Mol Nutr Food Res; 2019 Dec; 63(24):e1900927. PubMed ID: 31599067
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.
Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U
Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]